Tags

Type your tag names separated by a space and hit enter

Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Expert Rev Anti Infect Ther. 2011 Oct; 9(10):851-7.ER

Abstract

Oseltamivir and zanamivir are well-established and well-researched drugs for the treatment of influenza in Japan and the rest of the world. A new neuraminidase inhibitor, laninamivir octanoate, has been approved for use in Japanese clinics. Laninamivir octanoate is an inhaled drug with unique characteristics. The inhaled laninamivir octanoate is converted into its active form, laninamivir, in the lungs where a high concentration persists for a long period of time. The concentration of laninamivir exceeds the level necessary for influenza virus replication inhibition for at least 5 days, thus influenza can be treated with a single administration. The drug is delivered using one device requiring four inhalations for children and two devices requiring eight inhalations for adults. Clinical trials have shown comparable efficacy for laninamivir octanoate and oseltamivir. Laninamivir octanoate also displayed a sufficient antiviral effect to treat infection with H275Y-mutated oseltamivir-resistant virus. Laninamivir octanoate has displayed clinical efficacy comparable to that of oseltamivir and zanamivir against the H1N1 pandemic influenza strain from 2009, seasonal H3N2 influenza and influenza B viruses. The prophylactic efficacy of laninamivir octanoate has been shown in animal models. The effectiveness of laninamivir against the highly pathogenic avian influenza virus H5N1 has also been shown in vitro and in animal models. A major clinical benefit of this drug is that the single administration is very convenient for both the patient and doctor, which leads to improved compliance. Furthermore, this drug shows promise for the treatment of influenza in future pandemics.

Authors+Show Affiliations

Department of Clinical Trials, Center for Advanced Medical Innovation, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, Japan. ikematsu@gray.plala.or.jpNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21973296

Citation

Ikematsu, Hideyuki, and Naoki Kawai. "Laninamivir Octanoate: a New Long-acting Neuraminidase Inhibitor for the Treatment of Influenza." Expert Review of Anti-infective Therapy, vol. 9, no. 10, 2011, pp. 851-7.
Ikematsu H, Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther. 2011;9(10):851-7.
Ikematsu, H., & Kawai, N. (2011). Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Review of Anti-infective Therapy, 9(10), 851-7. https://doi.org/10.1586/eri.11.112
Ikematsu H, Kawai N. Laninamivir Octanoate: a New Long-acting Neuraminidase Inhibitor for the Treatment of Influenza. Expert Rev Anti Infect Ther. 2011;9(10):851-7. PubMed PMID: 21973296.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. AU - Ikematsu,Hideyuki, AU - Kawai,Naoki, PY - 2011/10/7/entrez PY - 2011/10/7/pubmed PY - 2012/1/28/medline SP - 851 EP - 7 JF - Expert review of anti-infective therapy JO - Expert Rev Anti Infect Ther VL - 9 IS - 10 N2 - Oseltamivir and zanamivir are well-established and well-researched drugs for the treatment of influenza in Japan and the rest of the world. A new neuraminidase inhibitor, laninamivir octanoate, has been approved for use in Japanese clinics. Laninamivir octanoate is an inhaled drug with unique characteristics. The inhaled laninamivir octanoate is converted into its active form, laninamivir, in the lungs where a high concentration persists for a long period of time. The concentration of laninamivir exceeds the level necessary for influenza virus replication inhibition for at least 5 days, thus influenza can be treated with a single administration. The drug is delivered using one device requiring four inhalations for children and two devices requiring eight inhalations for adults. Clinical trials have shown comparable efficacy for laninamivir octanoate and oseltamivir. Laninamivir octanoate also displayed a sufficient antiviral effect to treat infection with H275Y-mutated oseltamivir-resistant virus. Laninamivir octanoate has displayed clinical efficacy comparable to that of oseltamivir and zanamivir against the H1N1 pandemic influenza strain from 2009, seasonal H3N2 influenza and influenza B viruses. The prophylactic efficacy of laninamivir octanoate has been shown in animal models. The effectiveness of laninamivir against the highly pathogenic avian influenza virus H5N1 has also been shown in vitro and in animal models. A major clinical benefit of this drug is that the single administration is very convenient for both the patient and doctor, which leads to improved compliance. Furthermore, this drug shows promise for the treatment of influenza in future pandemics. SN - 1744-8336 UR - https://www.unboundmedicine.com/medline/citation/21973296/Laninamivir_octanoate:_a_new_long_acting_neuraminidase_inhibitor_for_the_treatment_of_influenza_ L2 - http://www.tandfonline.com/doi/full/10.1586/eri.11.112 DB - PRIME DP - Unbound Medicine ER -